FDA

Representative Image. Grayscale Photo of Eggs on a Tray. Photo Source: Renato K. (Pexels)

December 25, 2024

FDA Elevates Costco Egg Recall to Highest Risk Level Over Salmonella Concerns

The U.S. Food and Drug Administration (FDA) has upgraded the Costco egg recall to Class I – its highest risk classification. The recall, initiated by Handsome Brook Farms on November 27, 2024,

Representative Image. A dog having the medical check-up. Photo Source: Gustavo Fring (Pexels)

Health·News·USA

FDA Warns: Librela Linked to 3,600+ Adverse Reactions, Including Seizures and Deaths in Dogs

The Food and Drug Administration’s Center for Veterinary Medicine has issued an urgent warning about Librela, a widely-used injectable medication for dogs with osteoarthritis, following reports of severe adverse effects including deaths. Between January 2023 and March 2024, over 3,600

December 21, 2024

FDA Recalls 7,107 Duloxetine Bottles Due to Cancer-Linked N-Nitroso Contamination Risk

Health·USA

Rising Pharmaceuticals has initiated a nationwide recall of 7,107 bottles of duloxetine after discovering contamination with N-nitroso-duloxetine, a chemical compound linked to cancer risks.

RFK Jr.’s Lawyer Petitioned FDA to Revoke Polio Vaccine Approval

Health·News·USA

Aaron Siri, a lawyer helping Robert F. Kennedy Jr., has filed petitions seeking to revoke FDA approval of the polio vaccine and suspend distribution

Alcon Laboratories Issues Voluntary Nationwide Recall of One (1) Lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count (Lot 10101), Due to Fungal Contamination

Health

Systane Eye Drops Recalled Nationwide Over Fungal Contamination

Alcon Laboratories has initiated a voluntary recall of one lot of Systane Lubricant Eye Drops Ultra PF after confirming fungal contamination in a sealed vial. The recall affects lot number 10101 with

Tejal Somvanshi

December 27, 2024

Representative Image. Woman Sleeping. Photo Source: Ivan Obeleninov (Pexels)

Health·News·USA

FDA Approves Zepbound: First Sleep Apnea Drug Reduces Breathing Events by 25/hour, 18% Weight Loss

The U.S. Food and Drug Administration (FDA) has approved Zepbound (tirzepatide), marking the first medication authorized for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The approval comes

Uttam Kumar

December 24, 2024